TWST — Stock Film
STOCK FILMSCENE 1/11TWST · $91.23
Stock Expert AI presents
TWST
Twist Bioscience Corporation
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Twist Bioscience Corporation. A quick introduction.

On the stock market since 2018, it operates in the world of health and science. It has 979 employees. Now — the numbers.

on the stock market since 2018
979 employees
$5.7B market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.2.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
Sales are growing, year after year.

Average growth of 30% a year over the last 4 years. Red columns mark years that ended in a loss.

$132.3M
2021
$203.6M
2022
$245.1M
2023
$313M
2024
$376.6M
2025
In the vault right now:
$0
DEBT: $137.3M
At this pace, that money lasts about 3 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
55
average

Profit indicators sit around the sector average.

FINANCIAL STRENGTH
44
weak

Clearly below the class average.

VALUATION
51
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
76
strong

Clearly above the class average — a step short of the very top.

PRICE MOMENTUM
95
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking8/10
A strong cash pile8/10
Heavy investment in the future10/10
WEAK SPOTS
Executives aren’t buying3/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 33% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 23% a year on average.

2
THE BRIGHT SIDE · 2/3
The product is selling

Sales run at $376.6M a year. A small number, but proof the product has real buyers.

3
THE BRIGHT SIDE · 3/3
Strong cash, light debt

There is $232.4M in the vault; even if every debt were paid off, $95.1M would remain.

1
THE RISKS · 1/3
Running at a loss

A loss of $77.7M against $376.6M in annual sales.

2
THE RISKS · 2/3
A wildly swinging price

This stock swings about 2.1 times as much as the market average. Big rallies — and big drops — can both happen fast.

3
THE RISKS · 3/3
Executives lean toward selling

Over the last 12 months, executives reported 158 sells against just 40 buys. Not an alarm bell by itself, but a number worth watching.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, TWST sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: TWST is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film